ProCE Banner Activity

CE / CME

Mastering Asparaginase Regimens in the Care of Pediatric and AYA Patients With Acute Lymphoblastic Leukemia

Video

In this on-demand webcast, learn how to optimize clinical outcomes for patients with acute lymphoblastic leukemia through the use of asparaginase-based therapy, including evidence-based strategies to prevent, mitigate, and manage treatment-associated adverse events.

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 17, 2024

Expiration: April 16, 2025

Share

Faculty

Emily Curran

Emily Curran, MD

Assistant Professor
Department of Internal Medicine
Division of Hematology and Oncology
University of Cincinnati Cancer Center
Cincinnati, Ohio

Stephen P. Hunger

Stephen P. Hunger, MD

Jeffrey E. Perelman Distinguished Chair in Pediatrics
Chief, Division of Pediatric Oncology
Director, Center for Childhood Cancer Research
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals Inc

Target Audience

This program is intended for pediatric oncologists and other healthcare professionals caring for children, adolescents, and young adults with ALL.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Acute Lymphoblastic Leukemia (ALL).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Delineate optimal methods of identifying, measuring, and monitoring AEs associated with asparaginase therapies, including subclinical hypersensitivity and silent inactivation, in the pediatric and AYA population undergoing treatment for ALL

  • Determine instances when introducing alternative formulations of asparaginase is appropriate, in alignment with established best practices for both reexposure to asparaginase preparations and use of recombinant asparaginase

  • Modify asparaginase-based treatment regimens, using evidence-based agents and approaches, to address hypersensitivity reactions and increase completion rates of asparaginase treatment in patients with ALL

  • Evaluate current clinical evidence and expert recommendations for implementing pediatric-inspired therapeutic regimens for ALL into treatment plans for adolescents and young adults

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Emily Curran, MD

Assistant Professor
Department of Internal Medicine
Division of Hematology and Oncology
University of Cincinnati Cancer Center
Cincinnati, Ohio

Emily Curran, MD: consultant/advisor/speaker: Dava Oncology, Jazz Pharmaceuticals, Kite Pharmaceuticals, Servier.

Stephen P. Hunger, MD

Jeffrey E. Perelman Distinguished Chair in Pediatrics
Chief, Division of Pediatric Oncology
Director, Center for Childhood Cancer Research
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Stephen P. Hunger, MD: individual publicly traded stock/stock options: Amgen; consultant/advisor/speaker: Amgen, Jazz, Servier.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 17, 2024, through April 16, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).